Theravance Biopharma
TBPH
104 hedge funds and large institutions have $1.1B invested in Theravance Biopharma in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
8% more funds holding
Funds holding: 96 → 104 (+8)
0.33% more ownership
Funds ownership: 86.07% → 86.4% (+0.33%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $1.22B → $1.1B (-$121M)
98% less call options, than puts
Call options by funds: $220K | Put options by funds: $13.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$27M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$2.65M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.39M |
| 4 |
JG
Jefferies Group
New York
|
+$2.32M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$22.6M |
| 2 |
BlackRock
New York
|
-$3.71M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.58M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.02M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$622K |
TBPH Hedge Fund Activity: Q1 2019 in Review
104 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2019, worth a combined $1.1B — down 9.9% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TBPH positions and 12 closed out — a net gain of 8 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $27M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22.6M sold.
- 104 institutional investors held Theravance Biopharma (TBPH) as of Q1 2019, up from 96 in Q4 2018.
- Funds reported $1.1B of Theravance Biopharma stock for Q1 2019, down 9.9% quarter-over-quarter.
- 20 funds opened new Theravance Biopharma positions in Q1 2019 and 12 closed out, a net change of +8 holders.
- The largest Theravance Biopharma buyer in Q1 2019 was Woodford Investment Management, an estimated $27M added.
- The largest Theravance Biopharma seller in Q1 2019 was Cormorant Asset Management, an estimated $22.6M sold.
Based on aggregated 13F filings for Q1 2019.